We intend to identify product opportunities from approved drugs where we see an opportunity to improve the clinical performance of the product either by increasing the effectiveness of the drug andor by decreasing unwanted side effects. Furthermore, a new drug formulation may accelerate the speed of action, improve convenience of dosing or obtain decreased food interaction with absorption. The MeltDose technology has allowed us conuty bring each of our product candidates from program initiation to first human dose (clinical studies) in less than 12 months.
We intend to develop these improved formulations internally as well as in collaboration with existing and future partners.
Our goal is to fayettd the value of our business by retaining substantial commercial rights or profit sharing opportunities to our products and developing them through a combination of in-house clinical development and out-licensing of both early- and late-stage programs.